Uncommon anal neoplasms

Kevin Billingsley, Lawrence E. Stern, Andrew M. Lowy, Morton S. Kahlenberg, Charles Thomas

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    The neoplasms of the anus discussed in this article are uncommon, and therefore lack a consistent diagnostic and treatment algorithm derived from prospective clinical trial datasets. There may be an opportunity to design prospective Phase II clinical trials, with established uniform surgical pathology, surgical technique guidelines, and endpoints. The American College of Surgeons Oncology Group may have an opportunity to design and carry out controlled clinical trials for select rare anal neoplasms. Such an effort may yield modern benchmarks with which to base subsequent patient care algorithms.

    Original languageEnglish (US)
    Pages (from-to)375-388
    Number of pages14
    JournalSurgical Oncology Clinics of North America
    Volume13
    Issue number2
    DOIs
    StatePublished - Apr 2004

    Fingerprint

    Anus Neoplasms
    Benchmarking
    Surgical Pathology
    Phase II Clinical Trials
    Controlled Clinical Trials
    Patient Care
    Clinical Trials
    Guidelines
    Therapeutics
    Datasets

    ASJC Scopus subject areas

    • Oncology
    • Surgery

    Cite this

    Uncommon anal neoplasms. / Billingsley, Kevin; Stern, Lawrence E.; Lowy, Andrew M.; Kahlenberg, Morton S.; Thomas, Charles.

    In: Surgical Oncology Clinics of North America, Vol. 13, No. 2, 04.2004, p. 375-388.

    Research output: Contribution to journalArticle

    Billingsley, Kevin ; Stern, Lawrence E. ; Lowy, Andrew M. ; Kahlenberg, Morton S. ; Thomas, Charles. / Uncommon anal neoplasms. In: Surgical Oncology Clinics of North America. 2004 ; Vol. 13, No. 2. pp. 375-388.
    @article{afe1de3e307344b3b542bde3e5e81e47,
    title = "Uncommon anal neoplasms",
    abstract = "The neoplasms of the anus discussed in this article are uncommon, and therefore lack a consistent diagnostic and treatment algorithm derived from prospective clinical trial datasets. There may be an opportunity to design prospective Phase II clinical trials, with established uniform surgical pathology, surgical technique guidelines, and endpoints. The American College of Surgeons Oncology Group may have an opportunity to design and carry out controlled clinical trials for select rare anal neoplasms. Such an effort may yield modern benchmarks with which to base subsequent patient care algorithms.",
    author = "Kevin Billingsley and Stern, {Lawrence E.} and Lowy, {Andrew M.} and Kahlenberg, {Morton S.} and Charles Thomas",
    year = "2004",
    month = "4",
    doi = "10.1016/j.soc.2003.12.002",
    language = "English (US)",
    volume = "13",
    pages = "375--388",
    journal = "Surgical Oncology Clinics of North America",
    issn = "1055-3207",
    publisher = "W.B. Saunders Ltd",
    number = "2",

    }

    TY - JOUR

    T1 - Uncommon anal neoplasms

    AU - Billingsley, Kevin

    AU - Stern, Lawrence E.

    AU - Lowy, Andrew M.

    AU - Kahlenberg, Morton S.

    AU - Thomas, Charles

    PY - 2004/4

    Y1 - 2004/4

    N2 - The neoplasms of the anus discussed in this article are uncommon, and therefore lack a consistent diagnostic and treatment algorithm derived from prospective clinical trial datasets. There may be an opportunity to design prospective Phase II clinical trials, with established uniform surgical pathology, surgical technique guidelines, and endpoints. The American College of Surgeons Oncology Group may have an opportunity to design and carry out controlled clinical trials for select rare anal neoplasms. Such an effort may yield modern benchmarks with which to base subsequent patient care algorithms.

    AB - The neoplasms of the anus discussed in this article are uncommon, and therefore lack a consistent diagnostic and treatment algorithm derived from prospective clinical trial datasets. There may be an opportunity to design prospective Phase II clinical trials, with established uniform surgical pathology, surgical technique guidelines, and endpoints. The American College of Surgeons Oncology Group may have an opportunity to design and carry out controlled clinical trials for select rare anal neoplasms. Such an effort may yield modern benchmarks with which to base subsequent patient care algorithms.

    UR - http://www.scopus.com/inward/record.url?scp=2342505767&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=2342505767&partnerID=8YFLogxK

    U2 - 10.1016/j.soc.2003.12.002

    DO - 10.1016/j.soc.2003.12.002

    M3 - Article

    C2 - 15137963

    AN - SCOPUS:2342505767

    VL - 13

    SP - 375

    EP - 388

    JO - Surgical Oncology Clinics of North America

    JF - Surgical Oncology Clinics of North America

    SN - 1055-3207

    IS - 2

    ER -